Kyprolis Regimen Reduces Risk of Death in Relapsed Multiple Myeloma Patients, Studies Show
Adding the proteasome inhibitor Kyprolis (carfilzomib) to the standard regimen of Revlimid (lenalidomide) and dexamethasone reduced the risk of…
News
KD025 Shows Promise for Chronic Graft-Versus-Host Disease, a Common Complication of Stem Cell Transplants
Kadmon reports that the first patient group treated in a Phase 2 trial of its drug KD025 for chronic graft-versus-host disease after going through…
Multiple Myeloma Research Foundation Is Planning $15 Million Immunotherapy Initiative
The Multiple Myeloma Research Foundation will be pumping $15 million into a cancer immunotherapy initiative over the next three years. The effort will start with the…
FDA Suspends Keytruda Combination Trials for Myeloma After Patient Deaths
The U.S. Food and Drug Administration (FDA) has ordered Merck to suspend two Phase 3 and part of a…
FDA Approves Lab Test to Help Detect Myeloma
The U.S. Food and Drug Administration (FDA) recently approved a lab test to aid in the detection and diagnosis of myeloma and a range of…
Bristol-Myers Squibb Issues Four-year Follow-up Findings for Empliciti Triple Combo Therapy
Treatment with Empliciti (elotuzumab) plus Revlimid (lenalidomide) and dexamethasone (ELd) in patients with relapsed/refractory multiple myeloma (RRMM) continued to show effectiveness in the Phase 3…
Potential Use of Ninlaro as Maintenance Therapy in Multiple Myeloma Shown in Phase 1/2 Trials
Patients with newly diagnosed multiple myeloma benefit significantly from a combination of Ninlaro (ixazomib) plus Revlimid (lenalidomide) and dexamethasone, followed by Ninlaro maintenance therapy, according…
76-year-old Don Wright Has New Goal After Completing 100 Marathons with Myeloma
Doctors told Don Wright he had five years to live when he was diagnosed with multiple myeloma in 2003. Instead of resigning himself to this…
FDA Will Review Amgen’s Request to Expand Use of Xgeva for Multiple Myeloma
The U.S. Food and Drug Administration (FDA) has accepted a supplemental biologics license application (sBLA) seeking to expand the currently approved indication of Xgeva…
FDA Approves Darzalex Combo Therapy for Previously Treated Multiple Myeloma Patients
The U.S. Federal Drug Administration has approved a combination of the immunotherapies Darzalex (daratumumab), Pomalyst (pomalidomide) and dexamethasone as a multiple myeloma treatment, according to…
Recent Posts
- Low muscle mass linked to worse outcomes with chemoradiotherapy
- Dordaviprone under FDA priority review for aggressive glioma type
- FDA decision on linvoseltamab in treating RRMM expected in July
- CUSP06 put on FDA fast track for platinum-resistant ovarian cancer
- Tuspetinib as part of triple-combo therapy showing potential in AML